Perico N, et al. - In this randomized and placebo-controlled trial, researchers assessed the renoprotective effect of octreotide long-acting release (octreotide-LAR) in autosomal dominant polycystic kidney disease (ADPKD), the most frequent genetically determined renal disease, patients at high risk of ESRD due to later-stage ADPKD. For this investigation, 100 patients with estimated glomerular filtration rate (GFR) 15–40 ml/min/1.73 m² were randomized to receive two 20-mg intramuscular injections of octreotide-LAR (n = 51) or sodium chloride (placebo; n = 49) every 28 days for 3 years. Investiagtors found that 3-year octreotide-LAR treatment did not significantly affect the decline in GFR vs placebo, but significantly slowed cyst growth and progression to end-stage kidney failure, especially in patients with more severe kidney failure (stage 4) to begin with, and was safe and well tolerated. Overall, the authors concluded that octreotide-LAR was well tolerated and during the study, there was no patient requiring interruption of treatment or even transient dose down-titration